Japanese ver.

AMED Public and Private Partnerships for Infectious Diseases R&D (APiD)
MDR Acinetobacter Critical Urgent
MDR Pseudomonas aeruginosa Critical Serious(MDR) Priority1
Carbapenem-R Enterobacterales Critical Urgent
Ceph-R (ESBL+) Enterobacterales Critical Serious Ceph-R
Drug-R Neisseria gonorrhoeae High Urgent(drug-R) Priority1
MDR/XDR Mycobacterium tuberculosis Serious(drug-R) Priority1
Nontuberculous Mycobacterium (NTM) Priority1
Clostridioides difficile Urgent(drug-R) Priority2
Vancomycin-R Enterococci (VRE) High Serious(drug-R) Priority2
Methicillin-R Staphylococcus aureus (MRSA) High Serious(MRSA) Priority2
Vancomycin-R Staphylococcus aureus High Priority2
Penicillin non-susceptible Streptococcus pneumoniae (PNSP) Medium Serious(drug-R) Priority2
Drug-R Mycoplasma genitalium Watch list Priority2
Candida auris Urgent Priority1
Drug-R Candida Serious(drug-R) Priority2
Azole-R Aspergillus fumigatus Watch list Priority2
Drug-R Helicobacter pyroli High Priority3
Multi-drug resistant Bacteroides fragilis Priority3
Drug-R Campylobacter High Serious(drug-R) Priority3
Drug-R Salmonella High Serious(drug-R) Priority3
Fluorloquinolone-resistant Shigella Medium Serious Priority3
βーlactamase-nonproducing ampicillin resistant Haemophilus influenzae (BLNAR) Medium
Erythromycin-R group A Streptococcus Concerning
Clindamycin-R group B Streptococcus Concerning

Priority 1 Bacterial or fungal infection which is difficult to be treated by existing antibiotics nationally and internationally1) and which is expected to develop new antibiotics urgently.
1) Public domains in MHLW, NIID, MOFA, WHO and CDC
Priority 2 Bacterial or fungal infection which is clinically treatable by combinations of existing antibiotics nationally and internationally but which is expected to develop new antibiotics near future.
Priority 3 Bacterial or fungal infection other than the above which requires continuous surveillance and basic research for R&D in order to prepare for medical need of new drug in future.
The pathogens not listed this table are categorized “Priority 3” at this moment.

[Special notes]
Approaches from new view points consider to be supported regardless the listed pathogens recognizing that innovative breakthrough is always required in R&D on AMR.

Regarding Priority, the relationship between the Japanese version, WHO version and CDC version is as follows.

WHO Critical High Medium  
CDC Urgent Serious Concerning Watch
AMED ID PPP Priority 1 Priority 2 Priority 3  
No discription